USANA Health Sciences published its annual report (Form 10-K) for FY 2025, reporting net sales of USD 925.26 million, up 8.3%. Net earnings attributable to shareholders fell 74.4% to USD 10.8 million, which management attributed to a lower operating margin and a higher effective tax rate. FY 2025 core nutritional net sales were USD 793.29 million, down 6.9%, driven mainly by a 14.8% decline in active Customers. Selling, general and administrative expenses rose USD 74.1 million, reflecting a higher cost mix from the Hiya direct-to-consumer segment. Cash and cash equivalents were USD 158.4 million, down 12.9%, and the company said it believes liquidity remains adequate to meet cash requirements and sustain operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. USANA Health Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000896264-26-000021), on March 16, 2026, and is solely responsible for the information contained therein.